Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Get Free Report)'s stock price hit a new 52-week high during mid-day trading on Wednesday . The stock traded as high as $317.45 and last traded at $316.77, with a volume of 236069 shares traded. The stock had previously closed at $308.71.
Analysts Set New Price Targets
Several equities analysts have commented on the company. UBS Group increased their price target on Alnylam Pharmaceuticals from $331.00 to $349.00 and gave the company a "buy" rating in a report on Friday, May 2nd. Citigroup lifted their target price on shares of Alnylam Pharmaceuticals from $338.00 to $351.00 and gave the stock a "buy" rating in a report on Friday, March 21st. JPMorgan Chase & Co. upped their price target on shares of Alnylam Pharmaceuticals from $330.00 to $338.00 and gave the company an "overweight" rating in a report on Thursday, June 12th. Canaccord Genuity Group lifted their price objective on Alnylam Pharmaceuticals from $385.00 to $390.00 and gave the stock a "buy" rating in a research note on Friday, March 21st. Finally, Royal Bank Of Canada increased their target price on Alnylam Pharmaceuticals from $310.00 to $330.00 and gave the company an "outperform" rating in a research note on Friday, March 21st. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and twenty-one have given a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $319.58.
Get Our Latest Research Report on Alnylam Pharmaceuticals
Alnylam Pharmaceuticals Trading Down 0.8%
The stock has a market cap of $40.38 billion, a P/E ratio of -148.18 and a beta of 0.22. The business's 50 day simple moving average is $277.63 and its 200 day simple moving average is $261.04. The company has a debt-to-equity ratio of 8.88, a current ratio of 3.04 and a quick ratio of 2.98.
Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last posted its earnings results on Thursday, May 1st. The biopharmaceutical company reported ($0.44) EPS for the quarter, missing the consensus estimate of ($0.37) by ($0.07). Alnylam Pharmaceuticals had a negative return on equity of 510.31% and a negative net margin of 11.49%. The company had revenue of $594.19 million for the quarter, compared to the consensus estimate of $584.32 million. During the same quarter last year, the business earned ($0.16) EPS. Alnylam Pharmaceuticals's quarterly revenue was up 20.2% compared to the same quarter last year. On average, analysts expect that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.
Insider Buying and Selling at Alnylam Pharmaceuticals
In other news, CEO Yvonne Greenstreet sold 19,297 shares of the business's stock in a transaction that occurred on Monday, June 2nd. The stock was sold at an average price of $306.00, for a total value of $5,904,882.00. Following the transaction, the chief executive officer now directly owns 48,948 shares of the company's stock, valued at $14,978,088. The trade was a 28.28% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 1.50% of the company's stock.
Hedge Funds Weigh In On Alnylam Pharmaceuticals
Institutional investors have recently bought and sold shares of the business. SVB Wealth LLC bought a new stake in shares of Alnylam Pharmaceuticals during the first quarter worth $27,000. Whipplewood Advisors LLC grew its holdings in Alnylam Pharmaceuticals by 208.8% during the 1st quarter. Whipplewood Advisors LLC now owns 105 shares of the biopharmaceutical company's stock worth $28,000 after acquiring an additional 71 shares during the last quarter. Bessemer Group Inc. increased its position in Alnylam Pharmaceuticals by 176.9% in the 1st quarter. Bessemer Group Inc. now owns 108 shares of the biopharmaceutical company's stock valued at $29,000 after acquiring an additional 69 shares in the last quarter. Larson Financial Group LLC increased its position in Alnylam Pharmaceuticals by 187.2% in the 4th quarter. Larson Financial Group LLC now owns 112 shares of the biopharmaceutical company's stock valued at $26,000 after acquiring an additional 73 shares in the last quarter. Finally, Park Square Financial Group LLC bought a new position in shares of Alnylam Pharmaceuticals in the fourth quarter worth about $28,000. Institutional investors own 92.97% of the company's stock.
Alnylam Pharmaceuticals Company Profile
(
Get Free Report)
Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.
Featured Stories
Before you consider Alnylam Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alnylam Pharmaceuticals wasn't on the list.
While Alnylam Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.